davidmicrocap Saturday, 03/23/19 09:57:47 PM Re: None Post # of 117 I am long on this one since the big drop. I am postulating if the drop is related to the absence of synergistic effect on MSSA. Of course the trial design at this scale was not for proving efficacy, but it did show some light on the potential effect of CF-301. Second, the MRSA proportion in Phase II is about 35-40%, it is suspicious if this composition can be sustained in Phase III, although management said this range of MRSA is expected. Since CF-301 is highly effective in MRSA but not in MSSA when used with SoC. The composition of the study population greatly affects the overall efficacy. In other words, if Phase III does not have MRSA portion like this time, then likely we are seeing reduced overall efficacy. For the left-sided endocarditis, I think it doesn't impose much pressure on stock price. I think from the very beginning, there is limited hope on left-sided endocarditis since it is really difficult to treat with medication. Daptomycin was also approved for bacteremia and right-sided endocarditis around 13 years ago. However, overall speaking, I think CF-301 likely to show effect on MRSA cases and maybe some effect on MSSA (if left-sided endocarditis is excluded, likely we may see somer effect in Phase III). Therefore, I still think CFRX is a good risk/reward candidate at this share price.